1DEWAN NA, GUTA NC, REDEPENNING LS,et sl. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potentialrole in evaluation and management[J]. Chest, 1993, 104(4):997.
2BAKHEET SM, SALEEM M, POWE J, et al. F-18 fluorodeoxyglucose chest uptake in lunginflammation and infection[J]. Clin Nucl Med, 2000, 25(4): 273.
3AHUJA V, COLEMAN RE, HERDON J, et al. The prognostic significance offlurodeoxyglucose positron emission tomography imaging for patients with nonsmall celllung carcinoma[J]. Cancer, 1998, 83(5): 918.
4HIGASHI K, UEDA Y, SEKI H, et al. Fluorine-18-FDG PET imaging is negative inbronchioloalveolar lung carcinoma[J]. J Nucl Med, 1998, 39(6): 1016.
6GUPTA NC, GRAEBER GM, BISHOP HA. Comparative efficacy of positron emissiontomography with fluorodeoxyglucose in evalution of small (<1 cm), intermediate (1 to 3cm), and large (>3 cm) lymph node lesions[J]. Chest, 2000, 117(3): 773.
7FARRELL MA, MCADAMS HP, HERDON JE, et al. Non-small cell cancer: FDG PET for nodalstaging in patients with stage Ⅰ disease[J]. Nuclear Medicine, 2000, 215(3): 886.
8WENG E, TRAN L, REGE S, et al. Accuracy and clinical impact of mediastinal lymphnode staging with FDG-PET imaging in potentially resectable lung cancer[J]. Am J ClinOncol, 2000, 23(1): 47.
9ERASMUS JJ, PATZ EF JR, MCADAMS HP, et al. Evaluation of adrenal masses in patientswith bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography[J].AJR Am J Roentgenol, 1997, 168(5): 1357.
10BURY T, BARRETO A, DAENEN F, et al. Fluorine-18 deoxyglucose positron emissiontomography for the detection of bone metastases in patients with non-small cell lungcancaer[J]. Eur J Nucl Med, 1998, 25(9): 1244.
